Patients & Caregivers
Contact Us
Français
Home
Overview
Major Accomplishments
Future Challenges
Biological Sciences
Medicinal Chemistry
Process Chemistry
Pharmaceutical R&D
Clinical Research
Informatics
Research Library
Working at Merck Frosst
Search Jobs, Submit Resume, Log on
Career Choices
Students and recent Grads
Careers Questions
Partners
Company Overview
Community Relations
Frequently Asked Questions
VIOXX® Information Center
Corporate News
Executive Speeches
Product News
Research & Development News
Media Contact
Newsroom
Corporate News
Photos
Executive Speeches
Product News
CANCIDAS
®
COSOPT
®
COZAAR
®
CRIXIVAN
®
EMEND
TM
FOSAMAX
®
FOSAVANCE
®
GARDASIL
®
INVANZ
®
ISENTRESS
TM
JANUVIA
TM
MAXALT
®
MENJUGATE
®
PROPECIA
®
PROSCAR
®
ROTATEQ
®
SINGULAIR
®
VARIVAX
®
III
VASOTEC
®
VIOXX
®
ZOCOR
®
EZETROL
®
Research & Development News
PHN/Shingles
Media Contact
SINGULAIR
®
Press Releases
March 27, 2008
Merck Statement on the FDA Early Communication of an Ongoing Safety Review of Montelukast (SINGULAIR
®
)
Sept 06, 2007
Back-to-school can mean back to the doctor's office for kids with asthma
Product Monograph / Prescribing Information / Product Information
Click here
Studies
Disease Fact Sheets
Pediatric Asthma
Product Fact Sheets
SINGULAIR® (montelukast sodium)
Photos
B-Roll
What's New
Contact
Media contacts
.
Printer friendly
This site is for residents of Canada. / This site was updated on May 2, 2008.
